Robert Hofmeister - Dec 9, 2021 Form 4 Insider Report for TCR2 THERAPEUTICS INC. (TCRR)

Role
Chief Scientific Officer
Signature
/s/ Margaret Siegel as Attorney-in-Fact
Stock symbol
TCRR
Transactions as of
Dec 9, 2021
Transactions value $
$0
Form type
4
Date filed
12/10/2021, 03:30 PM
Next filing
Apr 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TCRR Common Stock 45.9K Dec 9, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRR Stock Option (Right to Buy) Award $0 +100K $0.00 100K Dec 9, 2021 Common Stock 100K $5.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.